Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Fusion Antibodies (FAB) Share Price

Price 14.50p on 08-08-2025 at 13:00:20
Change 0.50p 3.57%
Buy 15.00p
Sell 14.00p
Last Trade: Sell 6,801.00 at 14.35p
Day's Volume: 4,167,386
Last Close: 14.00p
Open: 14.50p
ISIN: GB00BDQZGK16
Day's Range 14.50p - 14.50p
52wk Range: 2.90p - 16.50p
Market Capitalisation: £16.48m
VWAP: 15.62762p
Shares in Issue: 113.66m

Fusion Antibodies (FAB) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 6,801 14.35p Ordinary
13:58:01 - 08-Aug-25
Buy* 18,752 14.90p Ordinary
13:57:02 - 08-Aug-25
Buy* 16,751 14.90p Ordinary
13:56:55 - 08-Aug-25
Buy* 5,000 14.90p Ordinary
13:56:51 - 08-Aug-25
Buy* 4 14.90p Ordinary
13:56:37 - 08-Aug-25
Buy* 8,000 14.26p Ordinary
13:55:16 - 08-Aug-25
Buy* 25,000 14.50p Ordinary
13:54:45 - 08-Aug-25
Buy* 3,269 14.26p Ordinary
13:51:31 - 08-Aug-25
Sell* 3,113 14.10p Ordinary
13:50:00 - 08-Aug-25
Buy* 900 14.50p Ordinary
13:50:00 - 08-Aug-25
See more Fusion Antibodies trades

Fusion Antibodies (FAB) Share Price History

Time period:
to
Date Open High Low Close Volume
7th Aug 2025 (Thu) 12.00 14.00 14.00 14.00 4,792,639
6th Aug 2025 (Wed) 10.75 12.00 10.75 12.00 2,433,748
5th Aug 2025 (Tue) 11.50 11.50 9.25 10.75 3,614,214
4th Aug 2025 (Mon) 11.00 11.00 10.50 10.50 1,884,773
1st Aug 2025 (Fri) 10.25 11.25 10.50 11.00 1,587,978
31st Jul 2025 (Thu) 10.50 10.50 10.25 10.25 751,527
30th Jul 2025 (Wed) 10.00 11.00 10.00 10.50 1,623,454
29th Jul 2025 (Tue) 9.75 10.75 9.75 10.00 2,806,755
28th Jul 2025 (Mon) 8.75 9.75 7.75 9.75 2,021,945
25th Jul 2025 (Fri) 9.00 8.90 8.75 8.75 876,254
24th Jul 2025 (Thu) 9.05 9.02 9.02 9.02 2,722,055
23rd Jul 2025 (Wed) 7.75 9.00 9.00 9.00 4,339,492
22nd Jul 2025 (Tue) 8.15 8.15 7.75 7.75 1,307,813
21st Jul 2025 (Mon) 8.25 8.75 8.00 8.15 1,949,936
18th Jul 2025 (Fri) 7.60 8.25 7.60 8.25 2,054,522
17th Jul 2025 (Thu) 7.15 7.00 7.00 7.00 945,368
16th Jul 2025 (Wed) 6.75 7.80 7.15 7.15 2,171,223
15th Jul 2025 (Tue) 6.55 6.75 6.55 6.75 524,799
14th Jul 2025 (Mon) 6.30 6.55 6.30 6.55 655,034
11th Jul 2025 (Fri) 6.35 6.35 6.30 6.30 579,817
10th Jul 2025 (Thu) 6.15 6.35 6.15 6.35 763,845
9th Jul 2025 (Wed) 6.25 6.25 6.10 6.15 800,516
8th Jul 2025 (Tue) 6.30 6.30 6.25 6.25 87,147
See more Fusion Antibodies price history

Fusion Antibodies (FAB) Regulatory News

Date Source Headline
5th Aug 2025 7:00 am RNS Grant of U.S. Patent for OptiMAL
24th Jul 2025 10:56 am RNS Issue Notification: US Patent Update
11th Jul 2025 7:00 am RNS Director/PDMR Shareholding
2nd Jun 2025 7:00 am RNS Total Voting Rights
22nd May 2025 2:33 pm RNS Update on U.S. Patent for OptiMAL®
8th May 2025 7:00 am RNS-R Investor presentation
7th May 2025 7:00 am RNS Issue of shares to non-executive directors
6th May 2025 10:53 am RNS Director/PDMR Shareholding
6th May 2025 10:38 am RNS Holding(s) in Company
6th May 2025 7:00 am RNS Trading update
See more Fusion Antibodies regulatory news

Fusion Antibodies (FAB) Share News

TRADING UPDATES: Poolbeg upsizes offer; Glenveagh backs outlook

22nd May 2025 22:51

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Fusion Antibodies receives approval of grant funding application

4th Dec 2024 12:18

(Alliance News) - Fusion Antibodies PLC on Wednesday announced the approval of a grant funding application to The Northern Ireland Precision Biomarkers & Therapeutics consortium, of which it is a member. Read More

Fusion Antibodies interim loss narrows as revenue more than doubles

19th Nov 2024 13:10

(Alliance News) - Fusion Antibodies PLC on Tuesday said its loss narrowed in the first half of its current financial year, as revenue more than doubled. Read More

IN BRIEF: Fusion Antibodies expects interim revenue to double

8th Oct 2024 13:58

Fusion Antibodies PLC - Belfast-based contract researcher that provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Expects revenue of around GBP1.2 million for the six months to September 30, more than doubling from GBP541,000 at the same time last year. Its gross margin is expected to be 29%, compared to negative 16% the year prior. Fusion Antibodies expands its collaboration agreement with the National Cancer Institute in the six-month period to include the company's humanisation of the NCI's existing camelid nanobodies, and secures a new contract for an antibody based therapeutic with an unnamed US-based biotechnology company. It is also contracted to develop a bespoke OptiPhage library for an unnamed client. The company remains on track with its strategic goals. Read More

UK shareholder meetings calendar - next 7 days

1st Oct 2024 15:33

Read More

See more Fusion Antibodies news
FTSE 100 Latest
Value9,096.42
Change-4.35

Login to your account

Forgot Password?

Not Registered